A synthetic peptide for use as a blocking control in assays to test for specificity of MFN2 antibody, Alternative Names: Mitofusin 2 control peptide, Mitofusin 2 antibody Blocking Peptide, Anti-Mitofusin 2 Blocking Peptide, CMT2A Blocking Peptide, CMT2A2 Blocking Peptide, CPRP1 Blocking Peptide, HSG Blocking Peptide, KIAA0214 Blocking Peptide, MARF Blocking Peptide, MFN2 Blocking Peptide, Mitofusin 2, Mitofusin -2, Mitofusin 2, Mitofusin -2 Blocking Peptide, Mitofusin 2 Blocking Peptide
Aufreinigung
The antibody is affinity purified from rabbit antiserum by affinity chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide is removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
MFN2
(Mitofusin 2 (MFN2))
Hintergrund
MFN2 is a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. It is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke.